Abstract
To determine the efficacy of oral vitamin D [25(OH)D] in patients with active rheumatoid arthritis (RA) who are in methotrexate (MTX) therapy, patients receiving stable doses of MTX were randomized to one of two dose groups and received 12 weeks of double-blind vitamin D[25(OH)D] (50,000 IU per week) or matching placebo. The moderate and major efficacy measure was the proportion of patients with >0.6 and >1.2 improvement in RA based on the Disease Activity Score 28(DAS 28) at 12 weeks. Safety measures included adverse events and laboratory assessments. On a background of MTX, the percentage of patients with a moderate/major DAS 28 response at week 12 in the vitamin D groups (76/44%) was not significantly different from placebo (64.6/33.4%). Adverse events were typically mild and included small hepatic enzyme elevation; we did not have any undesirable events resulting in discontinuation of study drug. In patients with active RA receiving stable doses of MTX, vitamin D showed non-significant improvement in efficacy outcomes compared to placebo.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cutolo M, Otsa K, Laas K, Yprus M, Lehtme R, Secchi ME et al (2006) Circannual vitamin D serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. Clin Exp Rheumatol 24(6):702–704
Frediani B, Rossini M, Adami S, Bianchi G, Di Munno O, Sinigaglia L et al (2006) Study of vitamin D status of rheumatoid arthritis patients. Rationale and design of a cross-sectional study by the osteoporosis and metabolic bone diseases study group of the Italian Society of Rheumatology (SIR). Reumatismo 58(4):314–318
Kröger H, Penttilä IM, Alhava EM (1993) Low serum vitamin D metabolites in women with rheumatoid arthritis. Scand J Rheumatol 22(4):172–177
Cantorna MT, Mahon BD (2004) Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence, Exp Biol Med (Maywood) 229(11):1136–1142; 67(4):530–535. Epub 2007 Jul 31
Oelzner P, Müller A, Deschner F, Hüller M, Abendroth K, Hein G et al (1998) Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int 62(3):193–198
Cutolo M, Otsa K, Uprus M, Paolino S, Seriolo B (2007) Vitamin D in rheumatoid arthritis. Autoimmun Rev 7(1):59–64 Epub 2007 Aug 14
Costenbader KH, Feskanich D, Holmes M, Karlson EW, Benito-Garcia E (2008) vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann Rheum Dis
Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG (2004) Iowa Women’s Health Study. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women’s Health Study. Arthritis Rheum 50(1):72–77
Craig SM, Yu F, Curtis JR, Alarcón GS, Conn DL, Jonas B et al (2010) Vitamin D status and its associations with disease activity and severity in African Americans with recent-onset rheumatoid arthritis. J Rheumatol 37(2):275–281 Epub 2009 Dec 23
(2007) Cecil Text book of Medicine[book online]. 23rd edn Elsevier, Saunders
Arnson Y, Amital H, Shoenfeld Y (2007) Vitamin D and autoimmunity: new aetiological and therapeutic considerations; Ann Rheum Dis 66(9):1137–1142 Epub 2007 Jun 8
Andjelkovic Z, Vojinovic J, Pejnovic N, Popovic M, Dujic A, Mitrovic D et al (1999) Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol 17(4):453–456
Conflict of interests
None.
Ethical approval
Obtained from the ethics committee.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Salesi, M., Farajzadegan, Z. Efficacy of Vitamin D in patients with active rheumatoid arthritis receiving methotrexate therapy. Rheumatol Int 32, 2129–2133 (2012). https://doi.org/10.1007/s00296-011-1944-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-011-1944-5